Abstracts tagged "Ankylosing spondylitis (AS) and quality of life"

Abstract Number: 1012 • 2013 ACR/ARHP Annual Meeting
Disease Severity, Quality Of Life, and Productivity Loss Among Patients With Ankylosing Spondylitis In Germany
Jürgen Braun¹, Herbert Kellner², Regina Max³, Markus Rihl⁴, Elmar Schmitz-Bortz⁵, Hendrik Schulze-Koops⁶, Silke Zinke⁷, Tao Fan⁸, Qian Ding⁹ and Ramon Lyu⁹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Centre for Inflammatory Joint Diseases, Munich, Germany, ³University of Heidelberg, Heidelberg, Germany, ⁴German Society for Rheumatology Association, Traunstein, Germany, ⁵Rheumatology practice, Hattingen, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Rheumatological Office, Berlin, Germany, ⁸Merck & Co., Inc., Whitehouse Station, NJ, ⁹Merck & Co., Inc, Whitehouse Station, NJ
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic, inflammatory form of arthritis that primarily affects the spine, which can cause significant pain and lead to bone…
Abstract Number: 601 • 2012 ACR/ARHP Annual Meeting
Bath Ankylosing Spondylitis Functional Index (BASFI) Is a Better Indicator of Poor Quality of Life Than Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in Ankylosing Spondylitis: Results From SIRAS – the Scotland and Ireland Registry for Ankylosing Spondylitis
Gareth T. Jones¹, Linda E. Morton¹, Gary J. Macfarlane¹ and Scotland and Ireland Registry for Ankylosing Spondylitis², ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Aberdeen
Background/Purpose: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Functional Index (BASFI) are validated instruments used to determine disease activity and function amongst ankylosing spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].